2013-01-11 14:26:24 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to NatureWise Biotech & Medicals Corp and produced a Rating Update Report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering NatureWise Biotech & Medicals Corp (4732). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential NatureWise Biotech & Medicals Corp investor.
Report Summary: NatureWise Biotech & Medicals Corp is an average quality company with a positive outlook. NatureWise Biotech & Medicals Corp has strong business growth and is run by mediocre management. The trend in NatureWise Biotech & Medicals Corp fair value exchange rate against its closest rated-competitor, GENERAL BIOLOGICAL CORP., has been depreciating over the past 2 weeks. When compared to its closest competitor, NatureWise Biotech & Medicals Corp shows less overvaluation and is equally likely to outperform
The 3-page report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of NatureWise Biotech & Medicals Corp for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.